Highlights Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.27 ^CAD	-4.22%		-8.10%	+440.48%

May. 13	Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee	MT
May. 13	Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee	May. 13	MT
Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting	May. 13	MT
Medicenna Therapeutics Up 13% After Flagging Presentations	Apr. 24	MT
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR	Apr. 10	MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today	Apr. 09	MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine	Apr. 09	MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	Apr. 09	MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	Apr. 09	CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024	Apr. 09	MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting	Mar. 06	MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting	Mar. 06	CI
Medicenna Reports Q3 Net Loss $5.0 Million	Feb. 14	MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022	Feb. 14	MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors	Feb. 13	MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors	Feb. 13	MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors	Feb. 13	CI
Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab	Jan. 09	MT
Medicenna Brief: Commencing Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab	Jan. 09	MT
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab	Jan. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Highlights

Filters